Literature DB >> 22412192

NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.

Francesco Staehli1, Kristina Ludigs, Leonhard X Heinz, Queralt Seguín-Estévez, Isabel Ferrero, Marion Braun, Kate Schroder, Manuele Rebsamen, Aubry Tardivel, Chantal Mattmann, H Robson MacDonald, Pedro Romero, Walter Reith, Greta Guarda, Jürg Tschopp.   

Abstract

Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular proteins involved in innate-driven inflammatory responses. The function of the family member NLR caspase recruitment domain containing protein 5 (NLRC5) remains a matter of debate, particularly with respect to NF-κB activation, type I IFN, and MHC I expression. To address the role of NLRC5, we generated Nlrc5-deficient mice (Nlrc5(Δ/Δ)). In this article we show that these animals exhibit slightly decreased CD8(+) T cell percentages, a phenotype compatible with deregulated MHC I expression. Of interest, NLRC5 ablation only mildly affected MHC I expression on APCs and, accordingly, Nlrc5(Δ/Δ) macrophages efficiently primed CD8(+) T cells. In contrast, NLRC5 deficiency dramatically impaired basal expression of MHC I in T, NKT, and NK lymphocytes. NLRC5 was sufficient to induce MHC I expression in a human lymphoid cell line, requiring both caspase recruitment and LRR domains. Moreover, endogenous NLRC5 localized to the nucleus and occupied the proximal promoter region of H-2 genes. Consistent with downregulated MHC I expression, the elimination of Nlrc5(Δ/Δ) lymphocytes by cytotoxic T cells was markedly reduced and, in addition, we observed low NLRC5 expression in several murine and human lymphoid-derived tumor cell lines. Hence, loss of NLRC5 expression represents an advantage for evading CD8(+) T cell-mediated elimination by downmodulation of MHC I levels-a mechanism that may be exploited by transformed cells. Our data show that NLRC5 acts as a key transcriptional regulator of MHC I in lymphocytes and support an essential role for NLRs in directing not only innate but also adaptive immune responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22412192     DOI: 10.4049/jimmunol.1102671

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Post-transcriptional inhibition of luciferase reporter assays by the Nod-like receptor proteins NLRX1 and NLRC3.

Authors:  Arthur Ling; Fraser Soares; David O Croitoru; Ivan Tattoli; Leticia A M Carneiro; Michele Boniotto; Szilvia Benko; Dana J Philpott; Stephen E Girardin
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

Review 2.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 3.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

4.  NLRC5: a NOD-like receptor protein with many faces in immune regulation.

Authors:  Yue Zhao; Feng Shao
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

5.  Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Authors:  Christopher R Lupfer; Kate L Stokes; Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

6.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Authors:  Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 7.  Mechanisms and pathways of innate immune activation and regulation in health and cancer.

Authors:  Jun Cui; Yongjun Chen; Helen Y Wang; Rong-Fu Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.

Authors:  Xuancheng Guo; Taixiang Liu; Hengfei Shi; Jingjing Wang; Ping Ji; Hongwei Wang; Yayi Hou; Ren Xiang Tan; Erguang Li
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 9.  Expression regulation and function of NLRC5.

Authors:  Yikun Yao; Youcun Qian
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

Review 10.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.